AU Patent

AU2015326572A1 — A suspension

Assigned to Veriton Pharma Ltd · Expires 2017-04-27 · 9y expired

What this patent protects

A suspension comprising microgranules of a benzimidazole derivative suspended in an organic solvent. The average diameter of the microgranules is 100 to 1200 µm, and the suspension has a standing viscosity of 4000 to 7000 centipoise at 15 to 25º C, and the viscosity of the suspen…

USPTO Abstract

A suspension comprising microgranules of a benzimidazole derivative suspended in an organic solvent. The average diameter of the microgranules is 100 to 1200 µm, and the suspension has a standing viscosity of 4000 to 7000 centipoise at 15 to 25º C, and the viscosity of the suspension is 2500 to 4000 centipoise at 15 to 25º C when shaken.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015326572A1
Jurisdiction
AU
Classification
Expires
2017-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Veriton Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.